KPRX · Kiora Pharmaceuticals Inc
$2.62
-0.04 (-1.50%)
At close · Aug 28
Going-concern doubt
— cleared Aug 7, 2026
The latest filing no longer states the doubt (first flagged May 8, 2026).
View the 10-Q filed Aug 7, 2026Market Cap
$11.77M
Shares
4.42M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Brian M. Strem | President and Chief Executive Officer5 | $971,696 |
| Eric J. Daniels | MD, MBA Former Chief Development Officer6 | $957,504 |
| Melissa Tosca | Chief Financial Officer7 | $516,733 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Brian M. Strem | President and Chief Executive Officer5 | $954,883 |
| Eric J. Daniels | MD, MBA Chief Development Officer6 | $674,053 |
| Melissa Tosca | Chief Financial Officer7 | $534,187 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Brian M. Strem | President and Chief Executive Officer5 | $805,247 |
| Eric J. Daniels | MD, MBA Chief Development Officer6 | $669,953 |
| Melissa Tosca | Chief Financial Officer7 | $390,345 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Brian M. Strem | President and Chief Executive Officer4 | $714,182 |
| Eric J. Daniels | MD, MBA Chief Development Officer5 | $546,909 |
| Stephen From | Former Executive Chairman; former President and Chief Executive Officer8 | $381,852 |
| Sarah Romano | Former Chief Financial Officer7 | $171,238 |
| Melissa Tosca | Executive Vice President of Finance6 | $132,535 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Franz Obermayr | Former Acting Chief Executive Officer; former EVP Clinical Development | $581,457 |
| Sarah Romano | Former Chief Financial Officer7 | $512,231 |
| Stephen From | Former Executive Chairman; former President and Chief Executive Officer8 | $463,022 |
| Brian M. Strem | President and Chief Executive Officer4 | $443,981 |
| Eric J. Daniels | MD, MBA Chief Development Officer5 | $156,082 |
| Melissa Tosca | Executive Vice President of Finance6 | — |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Stephen From | Former Executive Chairman; former President and Chief Executive Officer | $883,205 |
| Sarah Romano | Former Chief Financial Officer | $453,643 |
| Michael Manzo | Vice President of Engineering | $406,962 |
| Franz Obermayr | Former Acting Chief Executive Officer; former EVP Clinical Development | $8,476 |
| Brian M. Strem | President and Chief Executive Officer | — |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Stephen From | Executive Chairman; Former President and Chief Executive Officer | $601,340 |
| Michael Manzo | Vice President of Engineering | $367,852 |
| Sarah Romano | Chief Financial Officer | $359,695 |
| Barbara Wirostko | — | $261,720 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Stephen From | President and Chief Executive Officer | $999,500 |
| Former Chief Medical | Officer | $433,750 |
| Michael Manzo | Vice President of Engineering | $427,375 |
| Sarah Romano | Chief Financial Officer | $348,125 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Praveen Tyle, Ph.D. | Class II Director | Appointed | 2026-06-11 |
| Aron Shapiro | Class II Director | Appointed | 2026-06-11 |
| Lisa Walters-Hoffert | Class II Director | Appointed | 2026-06-11 |
| Eric J. Daniels, M.D., MBA | Chief Development Officer | Resigned | 2026-04-02 |
| Kenneth Gayron | member of the Board | Resigned | 2024-07-01 |
| Melissa Tosca | Chief Financial Officer | Appointed | 2024-07-01 |
| Lisa Walters-Hoffert | member of the Board | Appointed | 2024-07-01 |
| Carmine Stengone | member of the Audit Committee and the Nominating and Corporate Governance Committee of the Board | Appointed | 2023-09-21 |
| Erin Parsons | Chair of the Compensation Committee of the Board | Appointed | 2023-09-21 |
| Praveen Tyle | Chairman of the Board | Appointed | 2023-09-21 |
| Carmine Stengone | member of the Board | Appointed | 2023-08-01 |
| Melissa Tosca | Executive Vice President of Finance | Appointed | 2022-09-16 |
| Susan L. Drexler | Interim Chief Financial Officer | Resigned | 2022-06-21 |
| Susan L. Drexler | principal accounting officer | Appointed | 2022-04-26 |
| Susan L. Drexler | Interim Chief Financial Officer | Appointed | 2022-04-26 |
| Brian M. Strem, Ph.D. | principal financial officer and principal accounting officer | Appointed | 2022-03-23 |
| Michael Meluzio, CPA | principal financial officer and principal accounting officer | Appointed | 2022-02-28 |
| Sarah Romano | Chief Financial Officer | Resigned | 2022-02-28 |
| Sarah Romano | Chief Financial Officer | Resigned | 2022-02-14 |
| Paul Chaney | non-executive Chairman of the Board | Appointed | 2022-02-01 |
| Stephen From | member of the Board | Resigned | 2022-02-01 |
| Stephen From | Executive Chairman | Resigned | 2022-02-01 |
| Erin Parsons | member of the Board | Appointed | 2022-02-01 |
| David Hollander, MD, MBA | member of the Board | Appointed | 2021-12-15 |
| Eric J. Daniels, MD, MBA | Chief Development Officer | Appointed | 2021-10-26 |
Key facts
CIK
1372514
CUSIP
49721T507
13F (30d)
23 filings
21 filers
Visit website
Investor relations